Sequoia China and Illumina Launch Sequoia China Smart Healthcare Genomics Incubator (Illumina Technology-Driven)

Exploring the vast frontiers of life sciences and genomics, have you ever entertained such visions and questions:

How do the high-profile genomics incubators in California’s San Francisco Bay Area and Cambridge, UK, nurture the world’s most active bio-genetic entrepreneurs? What is injecting a continuous stream of vitality into emerging global innovation hubs? What strategic collaboration will emerge from the strong alliance between top-tier global investment firms and leaders in global gene sequencing technology in China?

Earlier this year, Sequoia Capital China and Illumina (NASDAQ: ILMN) jointly announced the launch ofSequoia China Smart Healthcare Genomics Incubator (Powered by Illumina Technology), dedicated to supporting life sciences startups and driving their breakthroughs and development in the innovative application of gene technology.The incubator’s inaugural acceleration program will launch in fall 2021, with applications due by June 1, 2021.

If you are unwilling to settle for the current competitive landscape, if you seek a broader platform and greater room for expansion, and if you have the strength and confidence to evolve from “startup” to “strong enterprise,” then this ready-to-launch innovation initiative is an opportunity not to be missed—awaiting only your arrival!

During each six-month incubation cycle, with two cycles per year, selected startups will receiveSequoia China’s dedicated venture capital funding for genomics startups and its specialized, in-depth empowerment coaching; Illumina’s professional support in the field of genomics; and access to a genomics-focused vertical industry incubator located in Pudong, Shanghai. The incubator provides BSL-2 laboratories capable of conducting NGS testing (including the use of Illumina’s globally leading sequencing platforms and reagents), shared cell culture rooms, shared bacterial culture rooms, and multiple independent, customized exclusive laboratories.

The inaugural cohort of the Incubator’s Acceleration Program leverages the premier resources of Sequoia China and Illumina, offering a diversified, one-stop acceleration suite that includes laboratory technical guidance, one-on-one customized coaching on genomics applications and cutting-edge technologies, facilitation of industry chain project collaborations, professional workspace support, access to top-tier large-scale industry summits, small-to-medium industry salons, and investment and financing mentorship from frontline investors. We are committed to accompanying incubated enterprises throughout their entrepreneurial journey, forging ahead together.

Sequoia Capital China, as “entrepreneurs behind entrepreneurs,” has been steadily advancing its long-term investment strategy in the healthcare sector with a discerning eye. Over the past 16 years, it has invested in nearly 200 healthcare and medical companies distinguished by their strong technological attributes and high growth potential. This collaboration marks another significant strategic move for Sequoia China, following the recent establishment of the Sequoia Digital Intelligence Industry Incubation Center in Shanghai. Leveraging its extensive experience accumulated over many years in healthcare industry investments, Sequoia China is committed to empowering entrepreneurs.

As a global leader in gene sequencing and microarray technology, Illumina has successively launched operations in the United States and the United Kingdom since 2014.Illumina Accelerator, it has successfully incubated more than 45 genomics startups worldwide, helping them secure approximately $600 million in financing globally and enabling these emerging entrepreneurs to become key components of the global gene industry chain.

Illumina will also fully leverage itsIllumina for Startups (including the two Illumina accelerators established in the San Francisco Bay Area, USA, and Cambridge, UK)technical resources to empower this incubator. In the fall of 2021, early-stage Chinese entrepreneurs and teams in genomics will have access to world-class Illumina technology incubation resources domestically. Sequoia China will also leverage its diversified investment empowerment capabilities to transcend geographical and pandemic-related challenges, making significant investments to build a localized incubation ecosystem that drives the development of genomics in China.

As genomics gains momentum and opportunities arrive as promised,

With top-tier resources converging and multiple parties joining forces,

The olive branch of opportunity has been extended,

We’re Just Waiting for You to Join!

→Click to Access the Application Link Directly←

(Application Deadline: June 1, 2021)